BioWorld Asia

Feb. 26, 2003

View Archived Issues

Route To Antigen Presentation Provides Clues For Viral Vaccines

Xenova, QLT Suffer Setback In Pivotal Trial Of Cancer Drug

German Officials Call For Cloning Ban At Home, Around The World

PhotoCure Seeks U.S. Approval Of Basal Cell Carcinoma Therapy

Domantis Gets Milestone, Funds For Work In Domain Antibodies

Gene Signal Raises EUR2M To Push Angiogenesis Platform

Peptech Suffers On Uncertainty Of Royalties For TNF Product

Clavis Tests Lipid Vector Program With Trial Of Cytarabine Derivative

Other News To Note

NicOx Takes Hit On Data, Calls For Inquiry Into Stock Movement

PARIS - The share price of NicOx SA on the Nouveau Marché in Paris plummeted by more than 83 percent last week after AstraZeneca plc issued a statement in the names of both companies announcing that the recently completed Phase II trial of a drug candidate they are developing did not attain its primary therapeutic objective. (BioWorld International) Read More

European Ethics Advisers Want Scrutiny In Area Of Genetic Tests

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...